The ring-shaped cohesin complex maintains genome integrity through regulating sister-chromatid cohesion, DNA repair and transcription in eukaryotes [1] [2] [3] [4] [5] [6] . Dysregulation of cohesin and its regulators has been implicated in human cancers and developmental diseases 7, 8 . Cohesin consists of an Smc1-Smc3 heterodimer and a non-Smc heterodimer 1, 9 . The Smc1 and Smc3 ATPases heterodimerize through their hinge domains (Fig. 1a) . Scc1 binds to the ATPase domains of Smc1 and Smc3 through its C-and N-terminal winged-helix domains, respectively, forming a ring. In human somatic cells, Scc1 binds through its central region to either SA1 or SA2, two homologous huntingtin, elongation factor 3, A subunit and TOR (HEAT) repeat-containing proteins.
a r t i c l e s
The ring-shaped cohesin complex maintains genome integrity through regulating sister-chromatid cohesion, DNA repair and transcription in eukaryotes [1] [2] [3] [4] [5] [6] . Dysregulation of cohesin and its regulators has been implicated in human cancers and developmental diseases 7, 8 . Cohesin consists of an Smc1-Smc3 heterodimer and a non-Smc heterodimer 1, 9 . The Smc1 and Smc3 ATPases heterodimerize through their hinge domains (Fig. 1a) . Scc1 binds to the ATPase domains of Smc1 and Smc3 through its C-and N-terminal winged-helix domains, respectively, forming a ring. In human somatic cells, Scc1 binds through its central region to either SA1 or SA2, two homologous huntingtin, elongation factor 3, A subunit and TOR (HEAT) repeat-containing proteins.
The dynamics and mode of cohesin association with chromatin are tightly regulated by a set of cohesin regulators 2, 3, 10, 11 . In telophase, cohesin is loaded onto chromatin by the cohesin loader Scc2-Scc4 (refs. 12-15) . In G1, cohesin association with chromatin remains dynamic, and the chromatin-bound cohesin can be released by the cooperative actions of the adaptor protein Pds5 and the cohesin inhibitor Wapl (refs. 16-18) . During S phase, the cohesin protector sororin binds cohesin in part through Pds5 and antagonizes Wapl to establish cohesion [19] [20] [21] . During prophase in human somatic cells, the mitotic kinases Cdk1, Plk1 and Aurora B collaborate to phosphorylate cohesin and sororin, triggering Wapl-dependent cohesin release from chromosome arms [22] [23] [24] . A pool of cohesin at centromeres is protected by the Sgo1-PP2A complex [25] [26] [27] , which keeps cohesin and sororin in a hypophosphorylated state and maintains centromeric cohesion 28 . At the metaphase-anaphase transition, the proper kinetochore-microtubule attachment creates tension across sister kinetochores and silences the spindle checkpoint 29, 30 , thus leading to separase activation. Kinetochore tension also triggers a redistribution of Sgo1 from centromeres to kinetochores 31, 32 that is thought to inactivate Sgo1 and allow cohesin cleavage by active separase. Inactivation of Sgo1-mediated protection of centromeric cohesion leads to premature sister-chromatid separation and spindle checkpoint-dependent mitotic arrest 33, 34 .
The SA2-Scc1 heterodimer mediates the binding between cohesin and its regulators, including Scc2-Scc4, Pds5, Wapl and Sgo1 (refs. 28,35,36) . The mechanisms by which this non-Smc cohesin subcomplex coordinates these crucial molecular interactions are poorly understood. To gain structural insights into these interactions, we have determined the crystal structure of human SA2 bound to the SA2-binding region of Scc1 and have mapped the binding sites of Sgo1 and Wapl. Our results establish a competition between Sgo1 and Wapl in cohesin binding and implicate a role for this direct antagonism in centromeric cohesion protection.
Identification of a binding hotspot between SA2 and Scc1
To ascertain the functional importance of the observed SA2-Scc1 interface, we created about 50 SA2 and Scc1 mutants targeting conserved, surface-exposed residues at or near the SA2-Scc1 interface. Strikingly, among these mutants, only one, SA2 D793K, abolished the binding between SA2 and Scc1 ( Fig. 2b and Supplementary  Fig. 1a-d) . SA2 D793 is located at site IV. Its side chain forms hydrogen bonds with the backbone amides of A377 and Q378 of Scc1, which reside in the loop connecting αC and αD (Fig. 2c) . In agreement with this result, deletion of P376 and A377 in this loop, deletion of αD or mutation of the three hydrophobic residues in αD abolished Scc1 binding to SA2 (Supplementary Fig. 1e ). Moreover, ectopic expression of Myc-SA2 wild type (WT), but not D793K, in HeLa cells rescued the premature sister-chromatid separation and mitotic arrest caused by co-depletion of SA1 and SA2 (Fig. 2d-g ). Therefore, SA2
and Scc1 interact through an extensive interface, with site IV being a binding hotspot. Interestingly, in the prefusion state of hemagglutinin (HA) of the influenza virus, an aspartate side chain of the fusion peptide forms similar hydrogen bonds to the backbone amides of residues a r t i c l e s npg a r t i c l e s in a pocket on HA 37 . Disruption of this interaction is a rate-limiting step in viral-membrane fusion.
Identification of a functional Sgo1-binding site on cohesin
Human Sgo1 associates with cohesin during mitosis, and phosphorylation of Sgo1 at T346 enhances this association 28 . It is unclear, however, whether the cohesin-Sgo1 interaction is direct. Through systematic deletion mutagenesis (data not shown), we mapped the cohesinbinding region of Sgo1 to a 41-residue conserved motif containing T346. Both the unphosphorylated Sgo1 and phospho-T346 Sgo1 (pSgo1) peptides bound purified recombinant SA2-Scc1 (Fig. 3a) . pSgo1 bound more tightly than unphosphorylated Sgo1 did. As determined by isothermal titration calorimetry (ITC), unphosphorylated Sgo1 bound SA2-Scc1 with a K d of 618 ± 80 nM (mean ± s.d. of three independent measurements), whereas pSgo1 had a K d of 109 ± 35 nM (Fig. 3b) . Both peptides bound SA2-Scc1 with a stoichiometry of 1:1, results indicating that SA2-Scc1 has a single Sgo1-binding site. Thus, Sgo1 binds directly to the SA2-Scc1 cohesin subcomplex, and Sgo1 phosphorylation enhances, but is not required for, this binding. Despite numerous attempts, we failed to obtain diffracting crystals of the SA2-Scc1-pSgo1 complex. The structural basis of phosphorylation-enhanced Sgo1 binding to cohesin remains to be established. We thus sought to define the Sgo1-binding site on SA2-Scc1 through mutagenesis. Among the SA2 and Scc1 mutations, SA2 Y297A, R298E, D326K, K330E, Y331A, W334A, D793K and K870E greatly diminished Sgo1 or pSgo1 binding in vitro ( Fig. 3c and Supplementary Fig. 2a,b) . The SA2 D793K mutant lost binding to Sgo1 because it could not bind Scc1. Another mutant, K870E, also had weakened Sgo1 binding. K870 is located at site IV, in proximity to D793. Mutation of this residue probably affects Sgo1 binding indirectly through affecting Scc1 binding. Aside from D793 and K870, all other residues critical for Sgo1 binding, including Y297, R298, D326, K330, Y331 and W334, are clustered near site II of the SA2-Scc1 interface (Fig. 3d) . When coexpressed with GFP-Sgo1 in HeLa cells, mutants targeting these residues also exhibited weaker binding to GFP-Sgo1 (Supplementary Fig. 2c) . Moreover, the Sgo1 binding-deficient SA2 mutants, Y297A, R298E, Y331A and W334A, failed to rescue the mitotic-arrest phenotypes of HeLa cells depleted of SA1 and SA2 (Fig. 3e,f and Supplementary  Fig. 2d,e) . Consistently with this, Y331A and W334A also failed to prevent premature sister-chromatid separation in these cells (Fig. 3g) . Collectively, these results establish site II of SA2-Scc1 as a functional Sgo1-binding site. The notion that Sgo1 binds near the SA2-Scc1 interface is also consistent with the fact that Sgo1 binds to only the SA2-Scc1 complex and does not associate with either SA2 or Scc1 alone (data not shown).
We noticed that a 2-(N-morpholino)ethanesulfonic acid (MES) molecule from the crystallization solution bound at the Sgo1-binding site ( Fig. 3d and Supplementary Fig. 3a,b) . In particular, the sulfate group of MES makes hydrogen bonds and favorable electrostatic interactions with Y297 and R298 and is in the vicinity of Y331. Y297 and R298 belong to a signature FVHRYRD motif conserved in SA proteins in eukaryotes from yeast to humans. SA2 Y297F and Y331F were defective in Sgo1 binding (Supplementary Fig. 2c ), thus implicating their hydroxyl groups in engaging in nonhydrophobic interactions with Sgo1. Thus, one intriguing possibility is that MES might mimic phospho-T346 of Sgo1. Future structural studies are needed to rigorously test this possibility.
The conserved FVHRYRD motif is involved in Scc2-Scc4 binding in fission yeast 35 . Mutations of this motif cause a partial defect in topological cohesin loading to circular DNA in vitro and a cohesion defect in yeast cells 35 . We tested whether this motif in human SA2 was also required for cohesin loading in human cells. GFP-SA2 Y297A and R298E localized to chromatin in telophase HeLa cells as efficiently as GFP-SA2 WT (Supplementary Fig. 3c,d) . As a negative control, the Scc1 binding-deficient D793K mutant did not associate npg a r t i c l e s with chromatin. Therefore, we do not have evidence to indicate a role for the FVHRYRD motif of human SA2 in cohesin loading. Because Scc2-Scc4 interacts with multiple cohesin subunits 35 , disruption of a single interaction surface might not block cohesin association with chromatin. Our results thus do not rule out a role of this motif in cohesin loading. Nevertheless, because SA2 Y297A and R298E do not show gross chromosome loading defects, their functional defects in human cells are probably due to their inability to bind Sgo1.
Sgo1 competes with Wapl for cohesin binding
SA2-Scc1 also interacts with Wapl. In particular, several FGF motifs in the N-terminal region of Wapl have been implicated in SA2-Scc1 binding 36 . In addition, we have previously shown that a middle region of human Wapl (Wapl-M, residues 510-570) is critical for SA2-Scc1 binding in vitro 38 (Fig. 4a) . We further tested whether Wapl-M was required for Wapl function in human cells. As expected, depletion of Wapl greatly increased the percentage of mitotic cells with armclosed sister chromatids (Fig. 4b,c) because cohesin was not effectively removed from chromosome arms, and sister chromosomes were not completely decatenated in Wapl-depleted cells [39] [40] [41] . Expression of wild-type Wapl, but not the mutant with Wapl-M deleted (∆510-570), rescued this arm-resolution deficiency. As expected from the wellestablished genetic antagonism between Sgo1 and Wapl in centromeric cohesion protection 17, 18 , depletion of Wapl from HeLa cells rescued the premature sister-chromatid separation and the resulting mitotic arrest caused by Sgo1 depletion ( Supplementary Fig. 4a,b) .
Restoring functional Wapl through increasing expression of Wapl wild type restored mitotic arrest in cells depleted of both Sgo1 and Wapl. When expressed at levels similar to those of wild type, Wapl ∆510-570 was less effective in restoring Wapl function and mitotic arrest in these cells. Collectively, our results suggest that the middle region of Wapl is critical for its function in human cells.
Because both Sgo1 and Wapl interact with SA2-Scc1, we tested whether Sgo1 and Wapl-M competed for binding to SA2-Scc1. A GST-Wapl fragment containing Wapl-M pulled down recombinant SA2-Scc1 purified from insect cells (Fig. 4d) . Addition of the pSgo1 peptide reduced SA2-Scc1 binding to GST-Wapl-M in a dosedependent manner (Fig. 4d,e) . As expected, the unphosphorylated Sgo1 peptide was less effective in the competition. As a control, a shorter pSgo1 peptide (with five residues flanking pT346 on either side) showed no competition.
We then mapped the Wapl-binding site on SA2-Scc1. We focused our analysis on the conserved patch of residues at the Sgo1-binding site (Fig. 4f,g ). Indeed, mutations of K290, D326 and K330 abolished Myc-SA2 binding to endogenous Wapl in human cells (Fig. 4h) . Mutations of Y331 and W334 in SA2 diminished (but did not abolish) Wapl binding in human cells. Four of the five Wapl binding-deficient SA2 mutants, including D326K, K330E, Y331A and W334A were also defective in Sgo1 binding. Mutation of SA2 Y328 had no effect on Wapl or Sgo1 binding. We further confirmed that the K290E, D326K and K330E mutations greatly reduced the binding of SA2-Scc1 to GST-Wapl-M in vitro ( Supplementary Fig. 4c,d ). Therefore, Sgo1 and Wapl compete with each other for cohesin binding, and they bind to overlapping sites on SA2-Scc1.
SA2 mutations or high concentrations of pSgo1 do not completely block Wapl binding to SA2-Scc1, thus suggesting that Wapl might bind SA2-Scc1 through multiple interfaces. In addition, the Wapland Sgo1-binding residues on SA2 are highly conserved in all metazoans, whereas the cohesin-binding motifs of Sgo1 and Wapl are conserved in only vertebrates and not in Drosophila or Caenorhabditis elegans. It is possible that certain conserved structural features of Sgo1 and Wapl cannot be easily gleaned from amino acid sequences alone. Alternatively, these SA2 residues are conserved for other purposes, such as binding Scc2-Scc4. a r t i c l e s Direct Sgo1-Wapl antagonism strengthens cohesion protection An established function of cohesin-bound Sgo1 is to recruit PP2A to cohesin and enable PP2A to protect sororin from phosphorylation by Cdk1 (ref. 28) . Hypophosphorylated sororin remains bound to Pds5 to counteract Wapl, thereby maintaining centromeric cohesion. Expression of the nonphosphorylatable sororin 9A mutant with all Cdk1 sites mutated has been shown to bypass the requirement for Sgo1 in cohesion protection during normal mitotic progression 24, 28 .
As shown above, pSgo1 binds to SA2-Scc1 with high affinity (around 100 nM) and directly competes with Wapl for cohesin binding. We thus examined whether the strong Sgo1 binding to SA2-Scc1 had additional roles aside from enabling sororin dephosphorylation by PP2A. We first revisited the phenotypes of sororin 9A-expressing cells depleted of Sgo1. As shown previously 28 , in the presence of nocodazole (which arrested cells in prometaphase, with all kinetochores not experiencing spindle-pulling force or tension), expression of sororin 9A in HeLa cells prevented premature sisterchromatid separation caused by Sgo1 depletion (Fig. 5a) . In stark contrast, in cells treated with the proteasome inhibitor MG132 (which arrested cells at metaphase, with persistent spindle-pulling force and kinetochore tension), Sgo1 depletion caused massive premature sister-chromatid separation even in cells expressing sororin 9A (Fig. 5a) . Thus, in the absence of the spindle-pulling force at kinetochores, hypophosphorylated sororin alone presumably suffices to protect centromeric cohesion. When kinetochores are under persistent tension, both Sgo1 and hypophosphorylated sororin are required to maintain sister-chromatid cohesion. This result suggests that, in addition to promoting sororin dephosphorylation, Sgo1 has other roles in cohesion protection.
We hypothesized that the direct competition between Sgo1 and Wapl for cohesin binding might allow Sgo1 to shield cohesin from Wapl and account for the sororin-independent function of Sgo1 in cohesion protection. A strong prediction of this hypothesis was that cohesin containing Wapl binding-deficient SA2 mutants should alleviate the need for Sgo1 protection. Indeed, overexpression of SA2 K290E, D326K or K330E mutants that lost Wapl binding in HeLa cells partially rescued the premature sister-chromatid separation (Supplementary Fig. 5a-c) and mitotic arrest (Fig. 5b) caused by Sgo1 depletion. As controls, expression of SA2 mutants that retained partial or full Wapl binding, including Y328A, Y331A and W334A, failed to bypass Sgo1 requirement in cohesion protection. Expression a r t i c l e s of other SA2 mutants targeting a conserved patch of residues in the C half or the Scc1 binding-deficient D793K mutant also had no effect. Finally, overexpression of SA2 D326K or K330E even rescued the gradual loss of cohesion in the presence of prolonged MG132-induced metaphase arrest, a phenotype termed cohesion fatigue 42 ( Supplementary Fig. 5d ). These results suggest that a critical function of Sgo1 in cohesion protection is to directly shield cohesin from Wapl through binding to SA2-Scc1.
DISCUSSION
In this study, we have determined the crystal structure of the SA2-Scc1 cohesin subcomplex, which is the interaction hub for cohesin regulators. Further biochemical and functional analyses have uncovered direct competition between the cohesion protector Sgo1 and the cohesion inhibitor Wapl for cohesin binding and have demonstrated the relevance of this competition in cohesion protection.
Sgo1 forms a homodimer through its N-terminal coiled-coil domain that binds PP2A 27 . One Sgo1 dimer binds to one PP2A complex 43 . We have shown that the pSgo1 peptide binds with 1:1 stoichiometry to SA2-Scc1. In principle, the two monomers of the Sgo1 dimer could each bind one cohesin complex, thus bridging two cohesin rings. We do not have evidence that this type of Sgo1-dependent cohesin crosslinking occurs in human cells. More importantly, the SA2 D326K and K330E mutants, which are defective in Sgo1 binding, can bypass the requirement for Sgo1 in cohesion, by virtue of their inability to interact with Wapl. Because these mutants cannot physically link cohesin rings, the putative Sgo1-mediated cohesin cross-linking (even if it does occur) is unlikely to directly contribute to sister-chromatid cohesion.
The results presented herein, along with previously published results, suggest the following model for cohesion establishment and maintenance in human cells (Fig. 5c) . During telophase and G1, cohesin is loaded on chromosomes but undergoes Wapl-dependent dynamic release from chromosomes. This release involves an opening of the cohesin ring at the Smc3-Scc1 juncture 44, 45 and requires an interaction between Pds5 and the N-terminal region of Wapl (Wapl-N) and interactions between cohesin and the middle region and C-terminal domain of Wapl. The mechanism by which Wapl-Pds5 disrupts the Smc3-Scc1 interface is unknown but is unlikely to be due to direct competition for binding 38, 46 . One possibility is that Wapl-Pds5 allosterically stimulates the intrinsic ATPase activity of cohesin, possibly by stabilizing the transition state. ATP hydrolysis transiently disrupts the Smc3-Scc1 interface and triggers the opening of the cohesin ring and its release from chromatin.
During S phase, Smc3 acetylation enables the binding of sororin to Pds5. Sororin blocks the Pds5-Wapl-N interaction but does not completely displace Wapl from cohesin 21, 28 because Wapl-M and Wapl-C can still associate with cohesin. This form of cohesin stably associates with sister chromatids and establishes cohesion. During mitosis, phosphorylation of sororin by mitotic kinases disrupts the sororin-Pds5 interaction 21 , and Wapl-N reengages Pds5 to trigger cohesin release from chromosome arms.
At centromeres, however, phosphorylated Sgo1 binds SA2-Scc1 to protect cohesin from Wapl in two ways. First, Sgo1 recruits PP2A to cohesin 28 , and this keeps sororin hypophosphorylated and bound to Pds5. Pds5-bound sororin antagonizes Wapl-N. Second, Sgo1 directly competes with Wapl-M for binding to SA2-Scc1. As a result, cohesin bound to both Sgo1 and sororin (indirectly through Pds5) is completely shielded from Wapl (ref. 28 ). These two mechanisms collaborate to protect centromeric cohesion to the fullest extent. Strong centromeric cohesion is required to resist the spindle-pulling force at sister kinetochores, and it enables the generation of kinetochore tension necessary for spindle-checkpoint inactivation and accurate chromosome segregation.
Another major function of shugoshin proteins is to protect meiotic cohesin at centromeres from separase-mediated cleavage during meiosis I 47, 48 . One mechanism by which shugoshin protects meiotic cohesin from separase is probably through PP2A-dependent dephosphorylation of Rec8 (the meiotic counterpart of Scc1) 43 . Human Sgo1 appears to be capable of inhibiting separase-dependent npg removal of mitotic cohesin from centromeres, when the Sgo1-cohesin interaction is not disrupted properly 31, 32 . Interestingly, the two separase-cleavage sites in human Scc1 flank the central SA2-binding region of Scc1 delineated in our structure 49 . In the future, it will be interesting to test whether SA2 contributes to Scc1 cleavage by providing a docking site for separase, and if it does so, to test whether Sgo1 binding to SA2-Scc1 also shields cohesin from separase.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Protein expression and purification. The cDNAs of human SA2 (residues 80-1060) and Scc1 (residues 281-420) were separately cloned into the FseI and AscI sites of a modified pFastBac HT vector (Invitrogen). The final constructs encoded an N-terminal His 6 -Flag-tagged SA2 and an N-terminal His 6 -streptagged Scc1, with a tobacco etch virus (TEV) protease cleavage site between the Flag tag and SA2, and a PreScission protease cleavage site between the strep tag and Scc1. Recombinant SA2 and Scc1 baculoviruses were constructed with the Bac-to-Bac system (Invitrogen) according to the manufacturer's protocols. For large-scale production of recombinant proteins, Hi5 insect cells (Sigma-Aldrich) were infected with both the SA2 and Scc1 baculoviruses and harvested at about 50 h after infection. Cells were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.7, 150 mM KCl, 0.1% (v/v) Triton X-100 and a protease-inhibitor cocktail). After sonication and centrifugation, the supernatant was applied onto Ni 2+ -NTA resin (Qiagen) equilibrated with lysis buffer, and incubated at 4 °C overnight. The resin was washed with wash buffer I (50 mM Tris-HCl, pH 7.7, 1.2 M KCl and 10 mM imidazole) and then washed with wash buffer II (20 mM HEPES, pH 7.4, 100 mM NaCl and 20 mM imidazole). The SA2-Scc1 complex was eluted with the elution buffer (20 mM HEPES, pH 7.4, 100 mM NaCl and 50-200 mM imidazole), and incubated with the TEV and PreScission proteases at 4 °C overnight.
The complex with the tags removed was applied onto a HiTrap Q HP column (GE Healthcare) equilibrated with the QA buffer (50 mM Tris-HCl, pH 8.5) with an AKTA chromatography system (GE Healthcare). SA2-Scc1 was eluted with a linear salt gradient from 0 to 600 mM NaCl. SA2-Scc1 was further applied onto a HiLoad 16/60 Superdex 200 prep-grade column (GE Healthcare) equilibrated with the purification buffer (20 mM Tris-HCl, pH 7.7, 300 mM NaCl and 5 mM TCEP). Purified SA2-Scc1 was concentrated to 7 mg/ml, flash frozen in liquid nitrogen and stored at −80 °C for crystallization or binding assays. The SeMet-labeled SA2-Scc1 complex was expressed in Hi5 cells according to the manufacturer's protocols. Briefly, Hi5 cells cultured in the ESF921 medium (Expression Systems) were infected with both SA2 and Scc1 baculoviruses. The cells were incubated for 16 h and then supplied with 100 mg/l l-selenomethionine. After an additional 48 h, the cells were harvested, and the SeMet SA2-Scc1 complex was purified as described above.
Crystallization and data collection. All crystallization experiments were performed at 20 °C. Initial screening for the SA2-Scc1-MES complex was carried out by sitting-drop vapor diffusion with a Phoenix crystallization robot (Art Robbins Instruments), with commercially available screening kits from Hampton Research, Qiagen and Molecular Dimensions. Conditions were further optimized with the hanging-drop vapor-diffusion method. SA2-Scc1-MES crystals suitable for X-ray-diffraction experiments appeared within 1 week with a reservoir solution consisting of 0.12 M Morpheus Divalents Mix, 0.1 M Morpheus Buffer System 1 and 27-30% (v/v) Morpheus EOD_P8K (Molecular Dimensions). Similarly, the SA2-Scc1 crystals were grown in 1 week with a reservoir solution consisting of 0.12 M Morpheus Divalents Mix, 0.1 M imidazole-HCl, pH 6.5, and 27-30% (v/v) Morpheus EOD_P8K. All crystals were cryoprotected with a reservoir solution including 30% (v/v) Morpheus EOD_P8K before being flash frozen.
All X-ray diffraction data were collected at 100 K at the Structural Biology Center (Beamline 19ID) at Argonne National Laboratory. SA2-Scc1-MES (Native-MES), SeMet-labeled SA2-Scc1-MES (SeMet-MES), and SeMet-labeled SA2-Scc1 without MES (SeMet) crystals diffracted to 2.95 Å, 2.85 Å and 3.05 Å, respectively ( Table 1) . Diffraction data were processed with the HKL package 50 . Structure determination and model refinement. Initial phases for the SeMetlabeled SA2-Scc1 were obtained by single-wavelength anomalous dispersion (SAD) with AutoSol in the PHENIX package 51 . Model building of the SA2 Nterminal HEAT repeats and Scc1 was done with AutoBuild in PHENIX. Subsequent model building was carried out with COOT 52 , and the structure was refined with PHENIX. Structures of the Native-MES and SeMet-MES complexes were solved by molecular replacement with PHENIX, with the SeMet structure (without MES) as the search model. Statistics for refinement are summarized in In vitro binding assays. The cDNAs encoding full-length human SA2, full-length human Scc1, and the Scc1 fragment (residues 211-420) were cloned into the FseI and AscI sites of a modified pCS2-Myc vector. The SA2 and Scc1 mutants were constructed with the QuikChange Site-directed Mutagenesis Kit (Stratagene). The pCS2-Myc-SA2 (wild type and mutants) or pCS2-Myc-Scc1 (wild type and mutants) vectors were added either alone or as a mixture of 3:1 ratio to the TNT Quick Coupled Transcription Translation System (Promega) and incubated in the presence of [ 35 S]methionine at 30 °C for 90 min to produce 35 S-labeled Myc-SA2, Myc-Scc1 or the Myc-SA2-Scc1 complex.
To assay the binding between SA2 and Scc1, GST-SA2 (residues 80-1060) and GST-Scc1 (residues 211-420) were expressed in bacteria and purified with the glutathione-Sepharose 4B resin (GE Healthcare). The glutathione-Sepharose beads bound to GST-SA2 or GST-Scc1 were incubated with 35 S-labeled Myc-Scc1 (wild type and mutants) or Myc-SA2 (wild type and mutants), respectively, at 4 °C overnight, and washed four times with TBS containing 0.05% Tween 20. Beads bound to GST were used as negative controls in both cases. The bound proteins were separated by SDS-PAGE. The gels were stained with Coomassie blue, dried and analyzed with a phosphorimager (Fujifilm). Intensities of bound proteins were quantified with ImageJ.
To assay the interaction between Sgo1 and SA2-Scc1, synthetic Sgo1 (residues 313-353) and phospho-T346 Sgo1 (pSgo1) peptides (each with an extra C-terminal cysteine) were coupled to beads with the SulfoLink Immobilization Kit and Coupling Resin (Thermo Scientific) according to the manufacturer's instructions. Recombinant purified SA2 80-1060 -Scc1 281-420 or the 35 S-labeled (wild-type and mutant) Myc-SA2-Scc1 211-420 complexes were incubated with Sgo1-or pSgo1-coupled beads at 4 °C overnight, and washed four times with TBS containing 0.05% Tween 20. The bound proteins were separated by SDS-PAGE and stained with Coomassie blue. For the assays with radioactive proteins, the gels were dried and analyzed with a phosphorimager (Fujifilm). Intensities of bound proteins were quantified with ImageJ.
To assay the binding between Wapl and SA2-Scc1, GST-Wapl 401-600 and GSTWapl 410-590 (wild-type and mutants) were expressed in bacteria and purified with glutathione-Sepharose 4B beads. Beads bound to GST or GST-Wapl proteins were incubated with recombinant purified SA2 80-1060 -Scc1 281-420 or the 35 S-labeled wild-type and mutant Myc-SA2-Scc1 211-420 complexes, in the presence of increasing concentrations of Sgo1 or pSgo1 peptides. The beads were washed with TBS containing 0.05% Tween 20. The bound proteins were analyzed and quantified as described above.
Isothermal titration calorimetry (ITC)
. ITC was performed with a MicroCal iTC200 (GE Healthcare) at 20 °C. Calorimetric measurements were performed with purified SA2-Scc1 and synthetic unphosphorylated or phospho-T346 Sgo1 peptides containing residues 313-353. For each titration, 300 µl of 23 µM SA2-Scc1 in a buffer containing 20 mM Tris-HCl, pH 7.7, 100 mM NaCl and 5 mM TCEP was added to the calorimeter cell. The Sgo1 or pSgo1 peptide (350 µM) in the same buffer was injected with 18 portions of 2 µl with an injection syringe. Binding parameters were evaluated with the Origin package provided with the instrument.
Cell culture, transfection and synchronization. HeLa Tet-On cells were grown in DMEM (Invitrogen) supplemented with 10% FBS and 2 mM l-glutamine. Plasmid transfection was performed when cells reached a confluency of 50% with the Effectene reagent (Qiagen) according to the manufacturer's protocols. For siRNA transfection, cells were transfected with Lipofectamine RNAiMAX (Invitrogen) at 20-40% confluency according to the manufacturer's protocols, and analyzed at 24-48 h after transfection. The siRNA oligonucleotides targeting human Wapl (siWapl; 5′-CGGACTACCCTTAGCACAA-3′), Sgo1 (siSgo1; 5′-GAGGGGACCCUUUUACAGATT-3′), SA1 (siSA1; 5′-GAAUAGAGA UGUUUCGAAA-3′) and SA2 (siSA2; 5′-CCACUGAUGUCUUACCGAA-3′) were synthesized by Thermo Scientific. The siRNAs were transfected at a final concentration of 5 nM.
For mitotic synchronization, cells were treated with 2 mM thymidine for 16-18 h, released into fresh medium for 9 h and blocked at mitosis with the addition of 5 µM nocodazole (Sigma) for 2 h. For the cohesin-loading assay, cells were treated with 2 mM thymidine for 16-18 h and released into fresh medium for 11 h before fixation. For the cohesion fatigue assay, cells were released into medium containing 10 µM MG132 for an additional 2 h after nocodazole (300 nM) treatment.
For stable cell lines, HeLa Tet-On cells were transfected with pTRE2-GFP vector encoding wild-type human Sgo1. Clones were selected with 200 µg/ml hygromycin B. Inducible expression of GFP-Sgo1 was screened in the absence or presence of 1 µg/ml doxycycline (Invitrogen).
Antibodies, immunoblotting and immunoprecipitation. The anti-Wapl antibody was generated against a C-terminal fragment of human Wapl (residues 601-1190) as described 5 . Rabbit polyclonal anti-GFP antibodies were raised against purified recombinant eGFP at Yenzym Antibodies. The following antibodies were purchased from the indicated commercial sources: anti-Myc (Roche, 11667203001), anti-SA2 (Santa Cruz, Biotechnology, sc-81852), anti-Scc1 (Bethyl Laboratories, A300-080A), anti-β-tubulin (Sigma, T4026) and MPM2 (Millipore, 05-368). The antibodies to Myc and Scc1 have been validated for immunoblotting and immunoprecipitation applications. The antibody to MPM2 has been validated for flow cytometry. The relevant validation information and references can be found at the manufacturers' websites. The antibody to SA2 is validated for immunoblotting in this study (Fig. 2d) , and the anti-GFP antibody is validated for both immunoblotting and immunoprecipitation (Supplementary Fig. 2c ).
For immunoblotting, cells were lysed in the SDS sample buffer (pH 6.8), sonicated and boiled. The lysates were separated by SDS-PAGE and blotted with the desired primary antibodies. The primary antibodies in the form of crude sera were used at 1:1,000 dilutions, whereas purified antibodies were used at a final concentration of 1 µg/ml. Horseradish peroxidase-linked donkey anti-rabbit or sheep anti-mouse IgGs (GE Healthcare) were used as secondary antibodies. Immunoblots were developed with the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) according to the manufacturer's protocols. Original images of gels, autoradiographs and blots in this study can be found in Supplementary Figure 6 .
For immunoprecipitation, the anti-Myc or anti-GFP antibodies were coupled to Affi-Prep Protein A beads (Bio-Rad) at a concentration of 1 mg/ml. Cells were lysed with the lysis buffer containing 25 mM Tris-HCl, pH 7.7, 75 mM NaCl, 0.1% (v/v) Nonidet P-40, 2 mM MgCl 2 , 10% (v/v) glycerol, 5 mM NaF, 0.3 mM Na 3 VO 4 , 10 mM β-glycerophosphate, 1 mM DTT, protease inhibitor mixture (Roche) and 50 units/ml Turbo Nuclease (Accelagen). After a 1-h incubation on ice and a 10-min incubation at 37 °C, all lysates were centrifuged at 4 °C at 20,817g for 20 min. The supernatants were incubated with the desired antibody beads for 3 h at 4 °C. The beads were then washed three times with the lysis buffer containing 200 mM NaCl. Proteins bound to beads were dissolved in SDS sample buffer, separated by SDS-PAGE and blotted with the appropriate antibodies.
Flow cytometry. Cells were harvested with trypsinization and fixed in 70% icecold ethanol overnight. After being washed with PBS, cells were permeabilized with PBS containing 0.25% Triton X-100 on ice for 5 min. Then cells were incubated with the antibody to MPM2 in PBS containing 1% BSA for 3 h at room temperature, and this was followed by an incubation with a fluorescent secondary antibody (Invitrogen) for 30 min. After being washed with PBS, cells were resuspended in PBS containing 0.1% Triton X-100, RNase A and propidium iodide, and then analyzed with a flow cytometer. Data were processed with FlowJo.
Immunofluorescence and metaphase spreads. After synchronization, mitotic HeLa Tet-On cells were collected by shake-off. Cells were washed once with PBS, treated with 55 mM KCl hypotonic solution at 37 °C for 15 min and spun onto microscope slides with a Shandon Cytospin centrifuge. Cells on the slides were first permeabilized with the PHEM buffer (25 mM HEPES, pH 7.5, 10 mM EGTA, pH 8.0, 60 mM PIPES, pH 7.0, and 2 mM MgCl 2 ) containing 0.3% Triton X-100 for 5 min and then fixed in 4% paraformaldehyde for 10 min. Fixed cells were washed three times with PBS containing 0.1% Triton X-100 for 2 min each time, and were incubated with CREST in PBS containing 3% BSA and 0.1% Triton X-100 at 4 °C overnight. Cells were then washed three times with PBS containing 0.1% Triton X-100 for 2 min each time, and were incubated with fluorescent secondary antibodies (Molecular Probes) in PBS containing 3% BSA and 0.1% Triton X-100 for 1 h at room temperature. Cells were again washed three times with PBS containing 0.1% Triton X-100 and then stained with 1 µg/ml DAPI for 2 min. After the final washes, the slides were sealed with nail polish and viewed with a 100× objective on a DeltaVision fluorescence microscope (GE Healthcare). Image processing and quantification were performed with ImageJ.
For the cohesin-loading assay, cells were plated in four-well chamber slides (LabTeck). Cells were transfected with GFP-SA2 plasmids for 8 h, and this was followed by siSA1 and siSA2 transfection for another 36 h. Cells were first extracted with PHEM buffer containing 0.5% Triton X-100 for 5 min and then were fixed in 2% paraformaldehyde for 15 min. After being washed with PBS, cells were blocked in PBS containing 2% BSA for 1 h, and were incubated with the anti-GFP and anti-tubulin antibodies in PBS containing 0.2% Triton X-100 and 3% BSA overnight at 4 °C. After being washed three times with PBS containing 0.05% Tween 20, cells were incubated with fluorescent secondary antibodies in PBS containing 0.2% Triton X-100 and 3% BSA for 1 h at room temperature. The cells were again washed three times with PBS containing 0.05% Tween 20 and stained with 1 µg/ml DAPI in PBS for 2 min. After final washes, slides were mounted and viewed with a 100× objective on a DeltaVision deconvolution fluorescence microscope. A series of z-stack images were captured at 0.2 µm intervals, deconvolved and projected. Image processing and quantification were performed with ImageJ. 
